ClinicalTrials.gg
RecruitingNCT07093580Updated Oct 16, 2026

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

A Phase 1 interventional study of S-892216-LAI and Placebo in Healthy Participants, sponsored by Shionogi. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Shionogi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 16, 2026Site recruiting status changedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
568th of 1,321
128 · median 91
Started
2025
with 45 others
Phase 1
178 of 1,859
10 open now
Primary completion
2028-06
later than 177 of 208 live
Registered
1,813th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 568th largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 46 that started in 2025, is one of 178 in phase 1, reaches primary completion later than 177 of the 208 other live ones, and was the 1,813th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

114 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.

03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • First-in-human (FIH)
  • Long-acting injectable (LAI) formulation
  • S-892216
  • S-892216-LAI
  • Severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2 infection
  • Novel Coronavirus
  • Coronavirus Disease 2019
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) ≥18.5 and ≤32.0 kilograms (kg)/square meter (m\^2)

Key Exclusion Criteria:

  • Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, or ophthalmological (for example, increased intra-ocular pressure) disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data per the investigator's assessment.
  • History of cancer except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Require medication or other treatment (for example, dietary restrictions or physical therapy).
  • Participated in any other clinical study involving an study intervention or any other type of medical research within 30 days, or 5 times the half-life of the investigational drug, before signing of the form (ICF) for this study or who are currently participating in such a study.
  • Positive test results of the following at screening or within 6 months prior to administration of study intervention: surface antigen (HBsAg); virus antibody (HCV); and (HIV) antigen/antibody.
  • Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR) test result, positive transcription-mediated amplification test result, positive antigen test result, or any other test approved according to local regulations at check in for each period on admission.
  • Known allergy/sensitivity or any to components of S-892216-LAI or placebo for S-892216-LAI.
  • Used cannabis (medical or recreational), tobacco, or nicotine-containing products (including e-cigarettes, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 6 months prior to admission.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Part 1 (Single Ascending Dose)

    Participants will receive a single dose of S-892216-LAI or placebo on Day 1.

    Drug: S-892216-LAI · Drug: Placebo

  • Experimental
    Part 2 (Multiple Ascending Dose)

    Participants will receive multiple doses of S-892216-LAI or placebo on Day 1 and Day 85 in treatment periods 1 and 2, respectively.

    Drug: S-892216-LAI · Drug: Placebo

Interventions

  • S-892216-LAI injection will be administered per schedule specified in the arm description.

  • DrugPlacebo

    Physiological saline will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 through Day 364

  2. Part 2: Number of Participants With TEAEs

    Time frame: Day 1 through Day 448

Secondary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 364

  2. Part 2: Cmax of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 70 in Treatment Period 1 and Day 85 (pre-administration, up to 12 hours post-administration) through Day 448 in Treatment Period 2

  3. Part 1: Time to Reach Cmax (Tmax) of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 364

  4. Part 2: Tmax of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 70 in Treatment Period 1 and Day 85 (pre-administration, up to 12 hours post-administration) through Day 448 in Treatment Period 2

  5. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration After Dosing (AUC0-last) of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 364

  6. Part 2: AUC0-last of S-892216 and its Metabolites

    Time frame: Day 1 (pre-administration, up to 12 hours post-administration) through Day 70 in Treatment Period 1 and Day 85 (pre-administration, up to 12 hours post-administration) through Day 448 in Treatment Period 2

07

Study locations

1 of 3 sites recruiting
  • Altasciences
    Cypress, California 90630, United States
    Recruiting
  • ICON Clinical Research: Lenexa
    Lenexa, Kansas 66219, United States
    Active, not recruiting

    Not enrolling at this site.

  • ICON Clinical Research: Salt Lake City
    Salt Lake City, Utah 84124, United States
    Active, not recruiting

    Not enrolling at this site.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 35 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 35 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion May 2027 → Jun 2028 and completion May 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Jun 30, 2028was May 2027
CompletionEst.
Jun 30, 2028was May 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now active, not recruiting)
Show 2 sites
  • ICON Clinical Research: Lenexa · Lenexa, United StatesRecruiting→Active, not recruiting
  • ICON Clinical Research: Salt Lake City · Salt Lake City, United StatesRecruiting→Active, not recruiting
Show site
  • Altasciences · Cypress, United States
Oct 16, 2026
Primary completion
May 26, 2027→Jun 30, 2028
Oct 6, 2026
Study completion
May 26, 2027→Jun 30, 2028
Oct 6, 2026
Enrollment
98→128
Oct 16, 2026
Eligibility
Sex MALE→ALL
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    1 site added. 2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • ICON Clinical Research: Lenexa · Lenexa, United StatesRecruiting→Active, not recruiting
    • ICON Clinical Research: Salt Lake City · Salt Lake City, United StatesRecruiting→Active, not recruiting
    Show site
    • Altasciences · Cypress, United States
    Enrollment 98→128
    Eligibility Sex MALE→ALL
    + 2 other changes: identifiers and verification date
  2. Oct 6, 2026
    Primary completion May 26, 2027→Jun 30, 2028
    Study completion May 26, 2027→Jun 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07093580
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Jul 29, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
Contact
Shionogiclintrials-admin@shionogi.co.jp
800-849-9707

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: S-892216

Start the discussion